If I had my way I'd make health catching instead of disease. - Robert Ingersoll

Drugs > Capecitabine News

You are currently reading Capecitabine news, below you will find the latest Capecitabine news available at Drug Topics. For more general Capecitabine information please visit Capecitabine. Capecitabine is categorized in the C index of drugs (by medical name) and in X index of drugs (by common name).

We have no matching items at this time. Please check back shortly.

Xeloda intake in early breast cancer extends life (PharmaBiz)
December 15, 2008, 8:51 pm

Data presented indicate that adding Xeloda to standard chemotherapy allows women to live cancer-free for longer.

Xeloda Shows Strong Promise in Early Breast Cancer (Presseportal)
December 14, 2008, 9:58 am

San Antonio, Texas (ots/PRNewswire) - - FOR NON-US DOMESTIC and NON-UK journalists only - Early Data Indicate Chemotherapy Pill Xeloda, Already Proven in Advanced Breast Cancer, May Also Reduce Recurrence of Early Breast Cancer ...

Roche?s Xeloda Medicine Keeps Breast Cancer at Bay in Study (Bloomberg)
December 14, 2008, 10:22 am

Dec. 14 (Bloomberg) -- Roche Holding AG ?s Xeloda pill helped prevent breast tumors from recurring, Finnish researchers said.

BMS announces positive data from Ixempra-capecitabine combo studies (PharmaBiz)
December 15, 2008, 11:51 pm

Copyright © Saffron Media Pvt. Ltd. Designed & Maintained by Fast Cursor

Significant Improvement In Progression-Free Survival For Triple Negative Metastatic Breast Cancer Patients Treated ... (Medical News Today)
December 15, 2008, 7:16 am

Bristol-Myers Squibb Company (NYSE:BMY) today announced new data from studies of IXEMPRA? (ixabepilone) plus capecitabine compared to capectabine alone, including a pre-specified sub set analysis demonstrating a significant increase in progression free survival (PFS) in patients with triple negative breast cancer.

Cancer Doctors Fear Chemo Drug Shortage (Forbes)
December 16, 2008, 12:10 pm

The inability of two drug makers to produce a generic cancer medicine endangers both patients and research.

Cytokinetics Announces Clinical And Preclinical Data Regarding Ispinesib For Breast Cancer Treatment (Medical News Today)
December 14, 2008, 4:16 am

Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that two posters, one summarizing interim Phase I clinical trial data evaluating ispinesib in the treatment of breast cancer and another containing preclinical data for ispinesib, were presented at the 31st Annual San Antonio Breast Cancer Symposium (SABCS) held on December 10-14, 2008.

Breast cancer drug combined with chemotherapy 'cuts recurrence by a third' (Daily Telegraph)
December 12, 2008, 10:15 am

Prescribing a breast cancer drug in addition to standard chemotherapy can cut the chances of the disease recurring by a third a new study shows.

Tyverb(R)/Tykerb(R) Plus Letrozole Significantly Delayed Disease Progression In Post-menopausal Women With ErbB2 ... (Medical News Today)
December 12, 2008, 9:16 am

New results from a study in metastatic breast cancer showed that the combination of Tyverb®/Tykerb® (lapatinib) plus letrozole as a first line treatment regimen provided a significant improvement in delaying disease progression when compared to treatment with Femara® (letrozole) alone.

Stronger role for a breast cancer drug (Science News)
December 11, 2008, 5:12 pm

Lapatinib shows utility for patients with a particularly troublesome form of the cancer

Drug Index

If you are researching a particular drug and know its common name use the alphabetical links below to quickly navigate to your desired subject.


If you are researching a particular drug and know its medical name use the alphabetical links below to quickly navigate to your desired subject.

Recommended Drug Sites

The following drug sites are listed in alphabetical order.

Recommended Health Sites

The following health sites are listed in alphabetical order.

Bookmark Us

The On Topic Network

This website is part of The On Topic Network.

Thank You

Drug-Topics.org was developed by Odin Metatech, Inc and runs on the Odin Assemble platform.


Powered by Odin Assemble 2.5a